NovoCure Limited (NVCR)
NASDAQ: NVCR · IEX Real-Time Price · USD
19.07
-0.11 (-0.55%)
Jun 21, 2024, 4:00 PM EDT - Market closed

NovoCure Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year
20232022202120202019 2018 - 2013
Net Income
-207.04-92.53-58.3519.81-7.23
Upgrade
Depreciation & Amortization
10.9710.6210.259.158.46
Upgrade
Share-Based Compensation
115.61106.9694.975.7252.42
Upgrade
Other Operating Activities
7.135.7435.96-5.53-27.03
Upgrade
Operating Cash Flow
-73.3430.7982.7699.1526.62
Upgrade
Operating Cash Flow Growth
--62.80%-16.53%272.46%-
Upgrade
Capital Expenditures
-27.09-21.36-24.17-14.97-10.49
Upgrade
Change in Investments
211.24-118.6-120.66-457.88-41.18
Upgrade
Investing Cash Flow
184.15-139.96-144.83-472.85-51.67
Upgrade
Share Issuance / Repurchase
4.425.224.553.372.47
Upgrade
Debt Issued / Paid
-0.01-0.03-0.03408.41-0.03
Upgrade
Other Financing Activities
11.3810.321.1828.4359.25
Upgrade
Financing Cash Flow
15.7915.4925.7440.2161.68
Upgrade
Exchange Rate Effect
0.13-0.1-0.190.250.03
Upgrade
Net Cash Flow
126.73-93.78-36.5666.7636.66
Upgrade
Free Cash Flow
-100.439.4358.5984.1816.14
Upgrade
Free Cash Flow Growth
--83.90%-30.40%421.72%-
Upgrade
Free Cash Flow Margin
-19.72%1.75%10.95%17.03%4.59%
Upgrade
Free Cash Flow Per Share
-0.940.090.570.830.17
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).